Assessment of coagulation system activation using spot urine measurements

Blood Coagulation and Fibrinolysis

Volumn 10, Issue 5, 1999, Pages 285-289

  Lind, S E ^a,c   Goldshteyn, S ^a   Barry, C P ^a   Lindquist, J R ^a   Piergies, A A ^a   Rosen, T ^b   Schneider, J R ^a   Shevrin, D H ^a   Caprini, J A ^a  

^a NORTHWESTERN UNIVERSITY   (United States)

^b NEW YORK UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c EVANSTON HOSPITAL   (United States)

Author keywords

Blood coagulation; Prothrombin; Urine

Indexed keywords

CREATININE; PEPTIDE FRAGMENT; PROTHROMBIN;

ADULT; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CREATININE URINE LEVEL; DIABETES MELLITUS; DIAGNOSTIC VALUE; FEMALE; HUMAN; HYPERCOAGULABILITY; MALE; PREGNANCY; PRIORITY JOURNAL; PROSTATE CANCER; PROTEIN URINE LEVEL; URINALYSIS; URINARY EXCRETION; VALIDATION PROCESS; VEIN THROMBOSIS;

EID: 0032784763     PISSN: 09575235     EISSN: None     Source Type: Journal    
DOI: 10.1097/00001721-199907000-00010     Document Type: Article

References (19)

1. 1. Aronson DL, Stevan L, Ball AP, Franza BR Jr, Finlayson JS. Generation of the combined prothrombin activation peptide (F1-2) during the clotting of blood and plasma. J Clin Invest 1977; 60: 1410-1418.
2. 2. Teitel JM, Bauer KA, Lau HK, Rosenberg RD. Studies of the prothrombin activation pathway utilizing radioimmunoassays for the F2/F1 + 2 fragment and thrombin-antithrombin complex. Blood 1982; 59: 1086-1097.
3. 3. Bauer KA, Rosenberg RD. The pathophysiology of the prethrombotic state in humans: insights gained from studies using markers of hemostatic system activation. Blood 1987; 70: 343-350.
4. 4. Miller GJ, Bauer KA, Barzegar S, Foley AJ, Mitchell JP, Cooper JA, et al. The effects of quality and timing of venepuncture on markers of blood coagulation in healthy middle-aged men. Thromb Haemost 1995; 73: 82-86.
5. 5. Alkjaersig N, Fletcher AP. Catabolism and excretion of fibrinopeptide-A. Blood 1982; 60: 148-156.
6. 6. Wilensky RL, Zeller JA, Wish M, Tulchinsky M. Urinary fibrinopeptide A levels in ischemic heart disease. J Am Coll Cardiol 1989; 14: 597-603.
7. 7. Tulchinsky M, Zeller JA, Reba RC. Urinary fibrinopeptide A in evaluation of patients with suspected acute pulmonary embolism. A prospective pilot study. Chest 1991; 100: 394-398.
8. 8. Bezeaud A, Aronson DL, Menache D, Guillin MC. Identification of a prothrombin derivative in human urine. Thromb Res 1978; 13: 551-556.
9. 9. Weinstock DM, Chang P, Aronson DL, Kessler CM. Comparison of plasma prothrombin and factor VII and urine prothrombin F1 concentrations in patients on long-term warfarin therapy and those in the initial phase. Am J Hematol 1998; 57: 193-199.
10. 10. Ryall RL, Grover PK, Stapleton AM, Barrell DK, Tang Y, Moritz RL, Simpson RJ. The urinary F1 activation peptide of human prothrombin is a potent inhibitor of calcium oxalate crystallization in undiluted human urine in vitro. Clin Sci 1995; 89: 533-541.
11. 11. Bezeaud A, Guillin M-C. Quantitation of prothrombin activation products in human urine. Br J Haematol 1984; 58: 597-606.
12. 12. Sorensen JV, Jensen HP, Rahr HB, Borris LC, Lassen MR, Knudsen F. F1 + 2 and FpA in urine from patients with multiple trauma and healthy individuals. A pilot study. Thromb Res 1992; 67: 429-434.
13. 13. Pelzer H, Schwarz A, Stüber W. Determination of human prothrombin activation fragment 1 + 2 in plasma with an antibody against a synthetic peptide. Thromb Haemost 1991; 65: 153-159.
14. 14. Ginsberg JM, Chang BS, Matarese RA, Garella S. Use of single voided urine samples to estimate quantitative proteinuria. N Engl J Med 1983; 309: 1543-1546.
15. 15. Levine AB, Teppa J, McGough B, Cowchock FS. Evaluation of the prethrombotic state in pregnancy and in women using oral contraceptives. Contraception 1996; 53: 255-257.
16. 16. Comeglio P, Fedi S, Liotta AA, Cellai AP, Chiarantini E, Prisco D, et al. Blood clotting activation during normal pregnancy. Thromb Res 1996; 84: 199-202.
17. 17. Falanga A, Ofosu FA, Delaini F, Oldani E, Dewar I., Lui L, et al. The hypercoagulable state in cancer patients: evidence for impaired thrombin inhibitions. Blood Coag Fibrinol 1994; 5 (suppl 1): S19-S23.
18. 18. Gruden G, Cavallo-Perin P, Romagnoli R, Olivetti C, Frezet D, Pagano G. Prothrombin fragment 1 + 2 and antithrombin III-thrombin complex in microalbuminuric type 2 diabetic patients. Diabet Med 1994; 11: 485-488.
19. 19. Ceriello A, Bortolotti N, Pirisi M, Crescentini A, Tonutti L, Motz E, et al. Total plasma antioxidant capacity predicts thrombosis-prone status in NIDDM patients. Diabetes Care 1997; 20: 1589-1593.